Immunologic mechanisms and treatment of myelodysplastic syndromes

Myelodysplastic Syndromes: Clinical and Biological Advances

Volumn , Issue , 2005, Pages 147-172

  Barrett, A John ^a   Sloand, Elaine ^a   Young, Neal S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928648761     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545269.007     Document Type: Chapter

References (76)

1. Mathe, G. and Schwarzenberg, L. (1976). Treatment of bone marrow aplasia by bone marrow graft after conditioning with antilymphocyte globulin. Long term results. Exp. Hematol., 4, 256–64.
2. Jeannet, M., Speck, B., Rubinstein, A. et al. (1976). Autologous marrow reconstitutions in severe aplastic anaemia afterALGpretreatment andHL-Asemi-incompatible bone marrow cell transfusion. Acta Haematol., 55, 129–39.
3. Speck, B. and Kissling, M. (1973). Studies on bone marrow transplantation in experimental 32P-induced aplastic anemia after conditioning with antilymphocyte serum. Acta Haematol., 50, 193–9.
4. Ascensao, J., Pahwa, R., Kagan, W. et al.(1976). Aplastic anaemia: evidence for an immunological mechanism. Lancet., 1, 669–71.
5. Gluckman, E., Devergie, A., Faille, A. et al.(1979). Antilymphocyte globulin treatment in severe aplastic anemia – comparison with bone marrow transplantation. Report of 60 cases. Haematol. Blood Transfus., 24, 171–9.
6. Young, N., Griffith, P., Brittain, E. et al.(1988). A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood, 72, 1861–9.
7. Biesma, D. H., van den Tweel, J. G., and Verdonck, L. F. (1997). Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer, 79, 1548–51.
8. Tichelli, A., Gratwohl, A., Wuersch, A., Nissen, C., and Speck, B. (1988). Antilymphocyte globulin for myelodysplastic syndrome. Br. J. Haematol., 68, 139–40.
9. Molldrem, J. J., Caples, M., Mavroudis, D. et al.(1997). Antithymocyte globulin for patients with myelodysplastic syndrome. Br. J. Haematol., 99, 699–705.
10. Molldrem, J. J., Leifer, E., Bahceci, E. et al.(2002). Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann. Intern. Med., 137, 156–63.
11. Jonasova, A., Neuwirtova, R., Cermak, J. et al. (1998). Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br. J. Haematol., 100, 304–9.
12. Killick, S. B., Mufti, G., Cavenagh, J. D. et al.(2003). A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low-risk’ myelodysplasia. Br. J. Haematol., 120, 679–84.
13. Yazji, S., Giles, F. J., Tsimberidou, A. M. et al.(2003). Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia, 17, 2101–6.
14. Grigg, A. P. and O’Flaherty, E. (2001). Cyclosporin A for the treatment of pure red cell aplasia associated with myelodysplasia. Leuk. Lymphoma, 42, 1339–42.
15. Billstrom, R., Johansson, H., Johansson, B., and Mitelman, F. (1995). Immunemediated complications in patients with myelodysplastic syndromes – clinical and cytogenetic features. Eur. J. Haematol., 55, 42–8.
16. Shimamoto, T. and Ohyashiki, K. (2003). Immunosuppressive treatments for myelodysplastic syndromes. Leuk. Lymphoma, 44, 593–604.
17. Hamblin, T. J. (1987). Myelodysplasia. Br. J. Hosp. Med., 38, 558–61.
18. Barrett, J., Saunthararajah, Y., and Molldrem, J. (2000). Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin. Hematol., 37, 15–29.
19. Maciejewski, J. P., Rivera, C., Kook, H., Dunn, D., and Young, N. S. (2001). Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones. Br. J. Haematol., 115, 1015–22.
20. Saunthararajah, Y., Nakamura, R., Nam, J. M. et al.(2002). HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood, 100, 1570–4.
21. Tuzuner, N., Cox, C., Rowe, J. M., and Bennett, J. M. (1994). Bone marrowcellularity in myeloid stem cell disorders: impact of age correction. Leuk. Res., 18, 559–64.
22. Dan, K., An, E., Futaki, M. et al.(1993).Megakaryocyte, erythroid and granulocytemacrophage colony formation in myelodysplastic syndromes. Acta Haematol., 89, 113–18.
23. Maciejewski, J. P., Kim, S., Sloand, E., Selleri, C., and Young, N. S. (2000). Sustained long-termhematologic recovery despite a marked quantitative defect in the stem cell compartment of patients with aplastic anemia after immunosuppressive therapy. Am. J. Hematol., 65, 123–31.
24. Maciejewski, J. P., Risitano, A., Sloand, E. M., Nunez, O., and Young, N. S. (2002). Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood, 99, 3129–35.
25. Cherry, A. M., Brockman, S. R., Paternoster, S. F. et al. (2003). Comparison of interphase FISH and metaphase cytogenetics to studymyelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leuk. Res., 27, 1085–90.
26. Fenaux, P. (2001). Chromosome and molecular abnormalities in myelodysplastic syndromes. Int. J. Hematol., 73, 429–37.
27. Cheson, B.D., Bennett, J. M., Kantarjian, H. et al. (2001).Myelodysplastic syndromes standardized response criteria: further definition. Blood, 98, 1985.
28. Rosenfeld, S., Follmann, D., Nunez, O., andYoung, N. S. (2003).Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. J.A.M.A., 289, 1130–5.
29. Shimamoto, T., Iguchi, T., Ando, K. et al.(2001). Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. Br. J. Haematol., 114, 358–61.
30. Young, N. S. (1992). The problem of clonality in aplastic anemia: Dr Dameshek’s riddle, restated. Blood, 79, 1385–92.
31. Young, N. S. and Maciejewski, J. P. (2000). Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes “why? why? why?” J. Clin. Invest., 106, 637–41.
32. Dunn, D. E., Tanawattanacharoen, P., Boccuni, P. et al. (1999). Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann. Intern. Med., 131, 401–8.
33. Chen, G., Kirby, M., Zeng, W., Young, N. S., and Maciejewski, J. P. (2002). Superior growth of glycophosphatidy linositol-anchored protein-deficient progenitor cells in vitro is due to the higher apoptotic rate of progenitors with normal phenotype in vivo (abstract). Exp. Hematol., 30, 774–82.
34. Chen, R., Nagarajan, S., Prince, G. M. et al.(2000). Impaired growth and elevated FAS receptor expression in PIGA(+) stem cells in primary paroxysmal nocturnal hemoglobinuria. J. Clin. Invest., 106, 689–96.
35. Rosenfeld, S., Follmann, D., Nunez, O., andYoung, N. S. (2003).Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. J.A.M.A., 289, 1130–5.
36. Gabor, E. P., Mishalani, S., and Lee, S. (1996). Rapid response to cyclosporine therapy and sustained remission in large granular lymphocyte leukemia. Blood, 87, 1199–200.
37. Wallis, W. J., Loughran, T. P., Jr., Kadin, M. E., Clark, E. A., and Starkebaum, G. A. (1985). Polyarthritis and neutropenia associated with circulating large granular lymphocytes. Ann. Intern. Med., 103, 357–62.
38. Bassan, R., Pronesti, M., Buzzetti, M. et al.(1989). Autoimmunity and B-cell dysfunction in chronic proliferative disorders of large granular lymphocytes/natural killer cells. Cancer, 63, 90–5.
39. Akashi, K., Shibuya, T., Taniguchi, S. et al.(1999).Multiple autoimmune haemopoietic disorders and insidious clonal proliferation of large granular lymphocytes. Br. J. Haematol., 107, 670–3.
40. Saunthararajah, Y., Molldrem, J. L., Rivera, M. et al.(2001). Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br. J. Haematol., 112, 195–200.
41. Battiwalla, M., Melenhorst, J., Saunthararajah, Y. et al.(2003). HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. Br. J. Haematol., 123, 449–53.
42. Baumann, I., Scheid, C., Koref, M. S. et al.(2002). Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelodysplastic syndrome. Exp. Hematol., 30, 1405–11.
43. Molldrem, J. J., Jiang, Y. Z., Stetler-Stevenson, M. et al.(1998). Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associatedwith a loss of lymphocyte-mediated inhibition ofCFU-GMand alterations in T-cell receptor Vbeta profiles. Br. J. Haematol., 102, 1314–22.
44. Greil, R., Anether, G., Johrer, K., and Tinhofer, I. (2003). Tuning the rheostat of the myelopoietic system via Fas and TRAIL. Crit. Rev. Immunol., 23, 301–22.
45. Plasilova, M., Zivny, J., Jelinek, J. et al.(2002). TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia, 16, 67–73.
46. Koike, M., Ishiyama, T., Tomoyasu, S., and Tsuruoka, N. (1995). Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia. Leuk. Res., 19, 639–44.
47. Kitagawa, M., Saito, I., Kuwata, T. et al.(1997). Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrowcells frompatients with myelodysplastic syndromes. Leukemia, 11, 2049–54.
48. Gersuk, G. M., Beckham, C., Loken, M. R. et al.(1998). A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br. J. Haematol., 103, 176–88.
49. Seaman, M. S., Peyerl, F.W., Jackson, S. S. et al.(2004). Subsets ofmemory cytotoxicT lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J. Virol., 78, 206–15.
50. Lima, M., Teixeira, M. A., Queiros, M. L. et al.(2003). Immunophenotype and TCRVbeta repertoire of peripheral blood T-cells in acute infectious mononucleosis. Blood Cells Mol. Dis., 30, 1–12.
51. Epperson, D. E., Nakamura, R., Saunthararajah, Y. et al. (2001). Oligoclonal T cell expansion inmyelodysplastic syndrome: evidence for an autoimmune process. Leuk. Res., 25, 1075–83.
52. Melenhorst, J. J., Eniafe, R., Follmann, D. et al.(2002).Molecular and flowcytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br. J. Haematol., 119, 97–105.
53. Plasilova, M., Risitano, A., andMaciejewski, J. P. (2003).Application of the molecular analysis of the T-cell receptor repertoire in the study of immune-mediated hematologic diseases. Hematology, 8, 173–81.
54. Melenhorst, J. J., Eniafe, R., Follmann, D. et al.(2003). T-cell large granular lymphocyte leukemia is characterized by massive TCRBV-restricted clonal CD8 expansion and a generalized overexpression of the effector cell marker CD57. Hematol. J., 4, 18–25.
55. Sloand, E. M., Kim, S., Fuhrer, M. et al.(2002). Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood, 100, 4427–32.
56. Oka, Y., Tsuboi, A., Murakami, M. et al.(2003). Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int. J. Hematol., 78, 56–61.
57. Cilloni, D., Gottardi, E., Messa, F. et al.(2003). Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J. Clin. Oncol., 21, 1988–95.
58. Elisseeva, O. A., Oka, Y., Tsuboi, A. et al. (2002).Humoral immune responses against Wilms tumor geneWT1 product in patientswith hematopoietic malignancies. Blood, 99, 3272–9.
59. Hosoya, N., Miyagawa, K., Mitani, K., Yazaki, Y., and Hirai, H. (1998). Mutation analysis of the WT1 gene in myelodysplastic syndromes. Jpn J. Cancer Res., 89, 821–4.
60. Rosenfeld, C., Cheever, M. A., and Gaiger, A. (2003).WT1 in acute leukemia, chronic myelogenous leukemia andmyelodysplastic syndrome: therapeutic potential ofWT1 targeted therapies. Leukemia, 17, 1301–12.
61. Tamaki, H., Ogawa, H., Ohyashiki, K. et al.(1999). The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia, 13, 393–9.
62. Klasa, R. J., List, A. F., and Cheson, B. D. (2001). Rational approaches to design of therapeutics targeting molecular markers. Hematology (Am. Soc. Hematol. Educ. Program), 443–62.
63. Kochenderfer, J. N. andMolldrem, J. J. (2001). Leukemia vaccines. Curr. Oncol. Rep., 3, 193–200.
64. Virtaneva, K., Wright, F. A., Tanner, S. M. et al. (2001). Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc. Natl Acad. Sci. U.S.A., 98, 1124–9.
65. Sloand, E. M., Mainwaring, L., Fuhrer, M. et al.(2005). Preferential suppression of trisomy 8 versus normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 versus normal hematopoietic cell growth by authologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood, 106, 841–51.
66. Catalano, L., Selleri, C., Califano, C. et al.(2000). Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica, 85, 133–8.
67. Atoyebi, W., Bywater, L., Rawlings, L., Brunskill, S., and Littlewood, T. J. (2002). Treatment of myelodysplasia with oral cyclosporin. Clin. Lab. Haematol., 24, 211–14.
68. Shimamoto, T., Tohyama, K., Okamoto, T. et al.(2003). Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk. Res., 27, 783–8.
69. Aivado, M., Rong, A., Stadler, M. et al.(2002). Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a ‘non-clonal’ pattern of X-chromosome inactivation in bone marrow cells. Eur. J. Haematol., 68, 210–16.
70. Steensma, D. P., Dispenzieri, A., Moore, S. B., Schroeder, G., and Tefferi, A. (2003). Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood, 101, 2156–8.
71. Geary, C. G., Harrison, C. J., Philpott, N. J. et al.(1999). Abnormal cytogenetic clones in patients with aplastic anaemia: response to immunosuppressive therapy. Br. J. Haematol., 104, 271–4.
72. Yamada, T., Tsurumi, H., Kasahara, S. et al.(2003). Immunosuppressive therapy formyelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A. J. Cancer Res. Clin. Oncol., 129, 485–91.
73. Miyata, A., Yasuda, Y., Fujii, S., and Kikuchi, T. [Outcome of immunosuppressive therapy formyelodysplastic syndromes: results of 12 cases from a single institution.] Rinsho Ketsueki, 43, 911–17.
74. Saunthararajah, Y., Nakamura, R., Wesley, R., Wang, Q. J., and Barrett, A. J. (2003). A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood, 102, 3025–7.
75. Stadler, M., Germing, U., Kliche, K. O. et al.(2004). A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia, 18, 460–5.
76. Cheson, B. D., Bennett, J. M., Kantarjian, H. et al.(2000). Report of an international working grouptostandardize response criteria formyelodysplastic syndromes. Blood, 96, 3671–4.